HONG KONG and PHNOM PENH from Cambodia, June 22, 2021 / PRNewswire / – from Cambodia The Ministry of Health has approved the INDICAID® COVID-19 rapid antigen test for commercialization as part of the country’s efforts to control recent spikes in COVID-19 cases in the region.
Rapid antigen tests like INDICAID® have been deployed by the Cambodian government for large-scale screening measures in the capital Phnom Penh and neighboring regions, taking advantage of the short duration of results and the convenience of testing to help the government quickly identify COVID-19 patients and curb the spread of the disease. These tests also allowed for better containment measures, effectively dividing the capital into red, orange and yellow zones depending on the number of cases and the risk of transmission. INDICAID® is also available in Phnom Penh for retail sale.
“We are confident that the accuracy, ease of use and affordability of our test kits will allow INDICAID® to play an important role in the Cambodian government’s ongoing screening efforts in the region.,“said Ricky chiu, Founder and CEO of PHASE Scientific, the official manufacturer of INDICAID® test kits. “We welcome the decision of the Cambodian government and look forward to bringing our rapid test kits to support its neighboring countries as well. “
According to Chiu, INDICAID® is being adopted in several countries to fight COVID-19. In Hong Kong, where PHASE Scientific is headquartered, INDICAID® has been approved by the government as a designated product for hospital and nursing home visits, and is the best-selling brand of its kind with over 2 million of kits sold. It has also been widely adopted in hospitals, government and private companies, supermarkets, hotels and schools for regular screening both locally and internationally.
The INDICAID® COVID-19 Rapid Antigen Test is a CE marked lateral flow immunoassay designed for the qualitative detection of SARS-CoV-2 antigens in direct nasal swab specimens. With reliable product quality and ease of use, INDICAID® can deliver rapid results in 20 minutes with no special equipment or installation required. The accuracy of the test kit has been clinically validated in the world’s largest dual-track clinical trial, where INDICAID® has been tested against PCR in over 9,200 samples and shown to demonstrate sensitivity and specificity high.
INDICAID® is currently available in 33 countries and in the process of obtaining Emergency Use Clearance (EUA) from the United States Food & Drug Administration (FDA).
PHASE SOURCE Scientific